Alectinib FoundationOne liquid companion diagnostic - Foundation Medicine
Alternative Names: Alectinib-FoundationOne® Liquid CDx - Foundation MedicineLatest Information Update: 07 Oct 2024
Price :
$50 *
At a glance
- Originator Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 19 Sep 2024 Launched for Non-small cell lung cancer in USA (unspecified route) prior to September 20204 (Foundation Medicine website, September 2024)